Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II

Contributed by: PR Newswire

Tags

Photocure-FDA

More Like This

Clinical data presentations at the European Association of Urology (EAU) 2025 congress highlight the benefits of using Blue Light Cystoscopy in bladder cancer

Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024

AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study

Bladder Cancer: Upstaging and risk mitigation with Blue Light Cystoscopy in NMIBC featured at ASCO GU 2025

Photocure and Intelligent Scopes Corporation partner on development of AI for blue light cystoscopy

Photocure and Richard Wolf Enter into Agreement to Develop a High-Definition Flexible Blue Light Cystoscope for Global Commercialization

Photocure Announces Mobile BLC Tower Initiative to Expand Access to Cysview in the U.S.

New Publication: Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy